News >

Expert Reviews Data for Abemaciclib in Breast Cancer

Published: Monday, Nov 26, 2018

Peter A. Kaufman, MD
Peter A. Kaufman, MD
The treatment options for women with hormone receptor (HR)–positive metastatic breast cancer have evolved rapidly in the past decade, with the introduction of the CDK4 and CDK6 inhibitors representing a major advance, according to Peter Kaufman, MD, during a lunch symposium at the 36th Annual CFS®.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication